Late-life rapamycin treatment reverses age-related heart dysfunction

Aging Cell

Volumn 12, Issue 5, 2013, Pages 851-862

  Flynn, James M ^a   O'Leary, Monique N ^a   Zambataro, Christopher A ^a   Academia, Emmeline C ^a   Presley, Michael P ^a   Garrett, Brittany J ^a   Zykovich, Artem ^a   Mooney, Sean D ^a   Strong, Randy ^b   Rosen, Clifford J ^c   Kapahi, Pankaj ^a   Nelson, Michael D ^d   Kennedy, Brian K ^a   Melov, Simon ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Maine Medical Center Research Institute   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Aging; Hypertrophy; MTOR; RAD; Rapamycin; RNA seq; Strain echocardiography

Indexed keywords

RAPAMYCIN;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; FEMALE; HEART; HEART DISEASE; HEART HYPERTROPHY; LIFESPAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RNA SEQUENCE;

MAMMALIA; MUS;

AGING; HYPERTROPHY; MTOR; RAD; RAPAMYCIN; RNA-SEQ; STRAIN ECHOCARDIOGRAPHY;

AGING; ANIMALS; CARDIOMYOPATHIES; DISEASE SUSCEPTIBILITY; ECHOCARDIOGRAPHY; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LONGEVITY; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 84883785478     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12109     Document Type: Article

References (45)

1. Aoyagi T, Matsui T (2011) Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr. Pharm. Des. 17, 1818-1824.
2. Aoyagi T, Kusakari Y, Xiao C-Y, Inouye BT, Takahashi M, Scherrer-Crosbie M, Rosenzweig A, Hara K, Matsui T (2012) Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am .J. Physiol. Heart Circ. Physiol. 303, H75-H85.
3. Astrinidis A, Kim J, Kelly CM, Olofsson BA, Torabi B, Sorokina EM, Azizkhan-Clifford J (2010) The transcription factor SP1 regulates centriole function and chromosomal stability through a functional interaction with the mammalian target of rapamycin/raptor complex. Genes Chromosom. Cancer 49, 282-297.
4. Bauer M, Cheng S, Jain M, Ngoy S, Theodoropoulos C, Trujillo A, Lin F-C, Liao R (2011) Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in mice. Circ. Res. 108, 908-916.
5. Blagosklonny MV (2006) Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 5, 2087-2102.
6. Buyse GM, Van der Mieren G, Erb M, D'hooge J, Herijgers P, Verbeken E, Jara A, Van Den Bergh A, Mertens L, Courdier-Fruh I, Barzaghi P, Meier T (2009) Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur. Heart J. 30, 116-124.
7. Chakravarty EF, Hubert HB, Lingala VB, Fries JF (2008) Reduced disability and mortality among aging runners: a 21-year longitudinal study. Arch. Intern. Med. 168, 1638-1646.
8. Chang L, Zhang J, Tseng Y-H, Xie C-Q, Ilany J, Brüning JC, Sun Z, Zhu X, Cui T, Youker KA, Yang Q, Day SM, Kahn CR, Chen YE (2007) Rad GTPase deficiency leads to cardiac hypertrophy. Circulation 116, 2976-2983.
9. Dai D-F, Santana LF, Vermulst M, Tomazela DM, Emond MJ, MacCoss MJ, Gollahon K, Martin GM, Loeb LA, Ladiges WC, Rabinovitch PS (2009) Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation 119, 2789-2797.
10. Darcy A, Meltzer M, Miller J, Lee S, Chappell S, Ver Donck K, Montano M (2012) A novel library screen identifies immunosuppressors that promote osteoblast differentiation. Bone 50, 1294-1303.
11. Fang Y, Westbrook R, Hill C, Boparai RK, Arum O, Spong A, Wang F, Javors MA, Chen J, Sun LY, Bartke A (2013) Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab. 17, 456-462.
12. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault M-F, Magnan C, Cerasi E, Kaiser N, Leibowitz G (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57, 945-957.
13. Freund A, Orjalo AV, Desprez P-Y, Campisi J (2010) Inflammatory networks during cellular senescence: causes and consequences. Trends Mol. Med. 16, 238-246.
14. Gao X-M, Wong G, Wang B, Kiriazis H, Moore X-L, Su Y-D, Dart A, Du X-J (2006) Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J. Hypertens. 24, 1663-1670.
15. Goodman CA, Mayhew DL, Hornberger TA (2011) Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass. Cell. Signal. 23, 1896-1906.
16. de Groot LCPMG, Verheijden MW, de Henauw S, Schroll M, van Staveren WASENECA Investigators, (2004) Lifestyle, nutritional status, health, and mortality in elderly people across Europe: a review of the longitudinal results of the SENECA study. J. Gerontol. A Biol. Sci. Med. Sci. 59, 1277-1284.
17. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395.
18. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S (2004) Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr. Biol. 14, 885-890.
19. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638-1643.
20. McMahon G, Weir MR, Li XC, Mandelbrot DA (2011) The evolving role of mTOR inhibition in transplantation tolerance. J. Am. Soc. Nephrol. 22, 408-415.
21. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S (2004) Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109, 3050-3055.
22. Miller AM, Brestoff JR, Phelps CB, Berk EZ, Reynolds TH (2008) Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295, R1431-R1438.
23. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 66, 191-201.
24. Mizuguchi Y, Oishi Y, Miyoshi H, Iuchi A, Nagase N, Oki T (2010) Concentric left ventricular hypertrophy brings deterioration of systolic longitudinal, circumferential, and radial myocardial deformation in hypertensive patients with preserved left ventricular pump function. J. Cardiol. 55, 23-33.
25. Nadon NL, Strong R, Miller RA, Nelson J, Javors M, Sharp ZD, Peralba JM, Harrison DE (2008) Design of aging intervention studies: the NIA interventions testing program. Age (Dordr) 30, 187-199.
26. Ng D-L, Tie S-W, Ong P-C, Lim W-S, Tengku-Muhammad T-S, Choo Q-C, Chew C-H (2011) Rapamycin pre-treatment abrogates Tumour Necrosis Factor-α down-regulatory effects on LXR-α and PXR mRNA expression via inhibition of c-Jun N-terminal kinase 1 activation in HepG2 cells. Electro. J. Biotech. 14, 1-11.
27. Nishikimi T, Kuwahara K, Nakao K (2011) Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J. Cardiol. 57, 131-140.
28. Oh J-E, Han J-A, Hwang ES (2007) Downregulation of transcription factor, Sp1, during cellular senescence. Biochem. Biophys. Res. Commun. 353, 86-91.
29. Paoletti E, Cannella G (2009) Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin. Transplant. Proc. 41, S3-S5.
30. Puntmann VO, Taylor PC, Mayr M (2011) Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: systemic inflammation and aging - a mini-review. Gerontology 57, 295-303.
31. Ramanathan A, Schreiber SL (2009) Direct control of mitochondrial function by mTOR. Proc. Natl Acad. Sci. USA 106, 22229-22232.
32. Schieke SM (2006) The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem. 281, 27643-27652.
33. Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ (2007) Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1114-G1122.
34. Sheard PW, Anderson RD (2012) Age-related loss of muscle fibres is highly variable amongst mouse skeletal muscles. Biogerontology 13, 157-167.
35. Smink JJ, Leutz A (2010) Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases. J. Mol. Med. 88, 227-233.
36. Song X, Kusakari Y, Xiao C-Y, Kinsella SD, Rosenberg MA, Scherrer-Crosbie M, Hara K, Rosenzweig A, Matsui T (2010) mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am. J. Physiol. Cell Physiol. 299, C1256-C1266.
37. Syed FA, Melim T (2011) Rodent models of aging bone: an update. Curr. Osteoporos. Rep. 9, 219-228.
38. Tei C, Nishimura RA, Seward JB, Tajik AJ (1997) Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J. Am. Soc. Echocardiogr. 10, 169-178.
39. Tschöp MH, Speakman JR, Arch JRS, Auwerx J, Brüning JC, Chan L, Eckel RH, Farese RV, Galgani JE, Hambly C, Herman MA, Horvath TL, Kahn BB, Kozma SC, Maratos-Flier E, Müller TD, Münzberg H, Pfluger PT, Plum L, Reitman ML, Rahmouni K, Shulman GI, Thomas G, Kahn CR, Ravussin E (2012) A guide to analysis of mouse energy metabolism. Nat. Methods 9, 57-63.
40. Vellai T, Takacs-Vellai K, Zhang Y, Kovács AL, Orosz L, Müller F (2003) Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 426, 620.
41. Wang G, Zhu X, Xie W, Han P, Li K, Sun Z, Wang Y, Chen C, Song R, Cao C, Zhang J, Wu C, Liu J, Cheng H (2010) Rad as a novel regulator of excitation-contraction coupling and beta-adrenergic signaling in heart. Circ. Res. 106, 317-327.
42. Wilkinson JE, Burmeister L, Brooks SV, Chan C-C, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, Woodward MA, Miller RA (2012) Rapamycin slows aging in mice. Aging Cell 11, 675-682.
43. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25, 341-347.
44. Yada H, Murata M, Shimoda K, Yuasa S, Kawaguchi H, Ieda M, Adachi T, Murata M, Ogawa S, Fukuda K (2007) Dominant negative suppression of Rad leads to QT prolongation and causes ventricular arrhythmias via modulation of L-type Ca2+ channels in the heart. Circ. Res. 101, 69-77.
45. Yang S-B, Lee HY, Young DM, Tien A-C, Rowson-Baldwin A, Shu YY, Jan YN, Jan LY (2012) Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J. Mol. Med. 90, 575-585.